Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech

TLDR GSK is buying Rapt Therapeutics for $58 per share in cash, valuing the deal at $2.2 billion RAPT stock climbed 65.76% over the past week following the acquisition announcement The purchase gives GSK rights to ozureprubart, a food allergy drug in phase 2b trials Leerink Partners cut RAPT to Market Perform with a $58 [...]

The post Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech appeared first on Blockonomi.